Literature DB >> 17940069

Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif.

Ruth Rollason1, Viktor Korolchuk, Clare Hamilton, Peter Schu, George Banting.   

Abstract

We have previously shown that the integral membrane protein CD317 has both a conventional transmembrane domain near its N-terminus and a C-terminal glycosyl-phosphatidylinositol (GPI) anchor. With the possible exception of a minor topological variant of the prion protein, there remain no other convincing examples of a mammalian protein with such a topology. CD317 is localised to cholesterol-rich lipid microdomains ('lipid rafts') in the plasma membrane and is internalised from the cell surface for delivery to a juxta-nuclear compartment (most probably the TGN). We have now investigated the mechanism by which CD317 is internalised and find that this raft-associated integral membrane protein is internalised through a clathrin-dependent pathway, internalisation is dependent upon a novel dual-tyrosine-based motif in the cytosolic domain of CD317, the cytosolic domain of CD317 can interact with the mu subunits of the AP2 and AP1 adaptor complexes, interaction with AP1 is required for delivery of CD317 back to the TGN, and removal of the GPI anchor from CD317 reduces the efficiency of CD317 internalisation. Collectively, these data indicate that CD317 is internalised and delivered back to the TGN by the sequential action of AP2 and AP1 adaptor complexes and that, surprisingly, the clathrin-mediated internalisation of CD317 occurs more efficiently if CD317 is localised to lipid rafts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940069     DOI: 10.1242/jcs.003343

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  133 in total

1.  Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Authors:  Raphaël Vigan; Stuart J D Neil
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif.

Authors:  Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

3.  Cholesterol regulates micro-opioid receptor-induced beta-arrestin 2 translocation to membrane lipid rafts.

Authors:  Yu Qiu; Yan Wang; Ping-Yee Law; Hong-Zhuan Chen; Horace H Loh
Journal:  Mol Pharmacol       Date:  2011-04-25       Impact factor: 4.436

4.  Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes.

Authors:  Li Ye; Xu Wang; Jieliang Li; Jinping Liu; Servio H Ramirez; Jianguo Wu; Wenzhe Ho
Journal:  Innate Immun       Date:  2011-09-22       Impact factor: 2.680

5.  BST-2 binding with cellular MT1-MMP blocks cell growth and migration via decreasing MMP2 activity.

Authors:  Gongping Gu; Dejian Zhao; Ziming Yin; Ping Liu
Journal:  J Cell Biochem       Date:  2012-03       Impact factor: 4.429

6.  Inhibition of Lassa and Marburg virus production by tetherin.

Authors:  Toshie Sakuma; Takeshi Noda; Shuzo Urata; Yoshihiro Kawaoka; Jiro Yasuda
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

Review 7.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

Review 8.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  Stimulation of NF-κB activity by the HIV restriction factor BST2.

Authors:  Andrey Tokarev; Marissa Suarez; Wilson Kwan; Kathleen Fitzpatrick; Rajendra Singh; John Guatelli
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.